Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Martin Wermke's publication output changed over time?
ScholarIQpublication output · 2002–2023
Output grew0% over the shown period — from 1 works in 2002 to 1 in 2023.
1
1
1
1
1
1
1
2
1
1
2002201020112014201820192020202120222023
What are the most-cited papers on Martin Wermke?
ScholarIQmost cited works
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer, Gerhard Ehninger, Thomas Illmer
Blood. 20021,733 CitationsOPEN ACCESS
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Uwe Platzbecker, Martin Wermke, J. Radke, Uta Oelschlaegel, Franzi Seltmann, Alexander Kiani, I-M Klut, Holger Knoth, Christoph Röllig, Johannes Schetelig, Brigitte Mohr, Xina Graehlert, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede
S149476849. 2011397 CitationsOPEN ACCESS
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Armin Ehninger, Michael Krämer, Christoph Röllig, Christian Thiede, Martin Bornhäuser, Malte von Bonin, Martin Wermke, Anja Feldmann, Michael Bachmann, Gerhard Ehninger, Uta Oelschlägel, on behalf of the Study Alliance Leukemia
S2496263508. 2014355 CitationsOPEN ACCESS
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik
S2754803477. 2022334 CitationsOPEN ACCESS
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura C. Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen‐Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen Pettit, Bob Löwenberg, S. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan Davidson‐Moncada, Sergio Rutella, John F. DiPersio
Blood. 2020323 CitationsOPEN ACCESS
Related on ScholarIQ
Heidelberg University
Institution
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Paper
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Paper
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Paper
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Paper
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Paper